PMID- 23360626
OWN - NLM
STAT- MEDLINE
DCOM- 20130716
LR  - 20131121
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Linking)
VI  - 16
IP  - 2
DP  - 2013 Feb
TI  - Human leukocyte antigen class I alleles can predict response to pegylated 
      interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.
PG  - 68-73
AB  - BACKGROUND: Racial differences and broad spectrum response to anti-hepatitis C 
      (anti-HCV) therapy suggest a possible role for host genetic diversity in 
      treatment outcomes. We aim to determine the association and predictive value of 
      certain human leukocyte antigen (HLA) class I alleles with either susceptibility 
      to viral clearance or persistence following pegylated interferon (Peg-IFN) plus 
      ribavirin therapy in chronic hepatitis C (HCV) genotype 4 patients in Egypt.  
      METHODS: This study included 200 unrelated chronic HCV patients who received 
      Peg-IFN plus ribavirin therapy [112 patients with sustained virological response 
      (SVR) and 88 non-responders (NR)]. Serological testing of HLA class I antigens 
      (HLA-A and HLA-B alleles) were performed by standard complement-dependent 
      microlymphocytotoxicity assay.  RESULTS: The frequency of HLA-A01 was 
      significantly higher in SVR than in NR cases [OR: 0.51; 95% CI: 0.27-0.981; P = 
      0.042], while the frequency of alleles B38 (P = 0.011), B40 (P < 0.001) and B41 
      (P < 0.001) was significantly higher in NR cases (OR/95% CI: 7.05/(1.39-18.01), 
      10.31/3.14-36.1 . On logistic regression analysis, presence of the HLA-A01 allele 
      was associated with SVR  (OR: 0.50; 95% CI: 0.28-0.89; P = 0.02) and HLA-B38 can 
      predict non response to therapy (OR: 7.92; 95% CI: 1.67-37.54; P = 0.009) with an 
      overall accuracy of 60%.Severe fibrosis (OR: 3.035; 95% CI: 1.521-6.091; P = 
      0.002), high viremia (OR: 2.69; 95% CI: 1.11-6.53; P = 0.005) and steatosis (OR: 
      2.1; 95% CI: 1.002-3.90; P = 0.041) predicted no response with an overall 
      accuracy of 81.8%.  CONCLUSION: HLA-A01 and HLA-B38 alleles are associated with 
      and may have a role in the outcome of response to Peg-IFN plus ribavirin therapy 
      in Egyptian patients diagnosed with chronic HCV infection. The use of immunologic 
      markers to predict the outcome of treatment may help pharmacogenetic 
      personalization of treatment for HCV infection.
FAU - Farag, Raghda E
AU  - Farag RE
AD  - Tropical Medicine Unit, Mansoura University Hospital, Mansoura Faculty of 
      Medicine, Egypt. raghda.farag@yahoo.com
FAU - Arafa, Mona M
AU  - Arafa MM
FAU - El-Etreby, Shahira
AU  - El-Etreby S
FAU - Saudy, Niveen S
AU  - Saudy NS
FAU - Eldeek, Basem S
AU  - Eldeek BS
FAU - El-Alfy, Hatem A
AU  - El-Alfy HA
FAU - Goda, Inas F
AU  - Goda IF
FAU - Ali, Rabab M
AU  - Ali RM
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - 0 (Antiviral Agents)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Egypt
MH  - Female
MH  - Genes, MHC Class I/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/genetics/immunology
MH  - Humans
MH  - Interferons/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Ribavirin/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2013/01/31 06:00
MHDA- 2013/07/17 06:00
CRDT- 2013/01/31 06:00
PHST- 2013/01/31 06:00 [entrez]
PHST- 2013/01/31 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
AID - 004 [pii]
PST - ppublish
SO  - Arch Iran Med. 2013 Feb;16(2):68-73.